Published on: 02 September 2025

Background: MASLD, Type 2 Diabetes, and the Weight Loss Imperative

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a highly prevalent comorbidity in individuals with type 2 diabetes and overweight or obesity, with estimates suggesting that over 65% of patients with T2DM have MASLD and a substantial proportion presenting with metabolic dysfunction-associated steatohepatitis (MASH).
This condition is not only a precursor to hepatic fibrosis and cirrhosis but also a driver of cardiovascular morbidity. As such, weight loss remains the cornerstone of MASLD management, with even modest reductions in body mass showing meaningful improvements in hepatic steatosis. However, achieving and maintaining clinically significant weight loss remains challenging for many patients.

Study Overview: Naltrexone-Bupropion Plus Lifestyle Intervention

This post hoc analysis of a 56-week, randomized, double-blind, placebo-controlled trial involved 505 adults with type 2 diabetes, overweight or obesity, and MASLD 1. Participants were randomized in a 2:1 ratio to receive either naltrexone-bupropion (NB) sustained-release combination therapy or placebo, alongside structured lifestyle counselling.
The primary aim was to evaluate changes in hepatic steatosis and hepatic fibrosis risk using non-invasive tests (NITs):

• Hepatic Steatosis Index (HSI)
• Metabolic Dysfunction-Associated Fibrosis-5 (MAF-5)
• Fibrosis-4 (FIB-4)

Key Findings: Naltrexone-Bupropion Drives Greater Weight Loss

At Week 56, the naltrexone-bupropion group achieved significantly greater weight loss compared with placebo (−6.3 ± 7.2 kg vs. −2.5 ± 5.2 kg, p < 0.001).
Importantly, this weight reduction translated into measurable hepatic benefits:

• HSI Reduction: −2.94 with NB vs. −1.18 with placebo (p < 0.001)
• MAF-5 Reduction: −0.80 with NB vs. −0.31 with placebo (p = 0.003)
• FIB-4: No significant change in either group

Weight Loss Thresholds: ≥5% Reduction is Clinically Relevant

Subgroup analyses revealed that ≥5% weight loss was the critical threshold for significant improvements in both hepatic steatosis (HSI) and hepatic fibrosis risk (MAF-5).

• Participants with <5% weight loss saw no significant hepatic benefit, regardless of treatment arm.
• Those achieving ≥10% weight loss experienced the most pronounced improvements, particularly in HSI.

Correlation and Predictive Modelling

Correlation analyses demonstrated:

• Strong association between weight loss and HSI reduction (r = 0.796, p < 0.001)
• Moderate association between weight loss and MAF-5 improvement (r = 0.488, p < 0.001)
• No significant association between weight loss and FIB-4 (p = 0.590)

Multiple regression confirmed that weight change was the strongest independent predictor of improvements in hepatic indices and liver enzymes (ALT, AST), whereas demographic and baseline metabolic parameters were not significant predictors.

Interpretation: Weight Loss as the Central Mechanism

The findings reinforce that weight loss—rather than a direct pharmacologic hepatic effect—is the primary driver of improvement in hepatic steatosis and fibrosis risk. Nevertheless, naltrexone-bupropion provided a clinically meaningful advantage by helping patients achieve and sustain greater weight reduction compared to lifestyle intervention alone.

Clinical Implications for Muslim Weight Management

For healthcare professionals engaged in weight management in Muslim patients with type 2 diabetes and MASLD:

1. Naltrexone-bupropion can be considered as an adjunct to structured lifestyle modification when weight loss targets are not being met through lifestyle alone.
2. The therapeutic goal should be achieving ≥5% weight loss, with ≥10% as an optimal target for maximal liver benefit.
3. Non-invasive indices such as HSI and MAF-5 are more responsive to weight change in metabolic patients than FIB-4, and may be more suitable for longitudinal monitoring.
4. Weight loss strategies must also account for cultural, dietary, and behavioural factors relevant to Muslim populations, including fasting periods and traditional dietary patterns.

Limitations and Future Directions

While the results are promising, this was a post hoc analysis, and the NITs used were not originally designed for longitudinal MASLD follow-up. Moreover, HSI and MAF-5 incorporate BMI and waist circumference, which may confound their responsiveness to weight loss.
Future research should:

• Validate these findings against histological or advanced imaging endpoints.
• Explore the role of naltrexone-bupropion in diverse populations, including those with different cultural and dietary backgrounds.
• Assess long-term durability of hepatic improvements beyond 56 weeks.

Conclusion: Enhanced Weight Loss Translates to Better Liver Health

In patients with type 2 diabetes, overweight or obesity, and MASLD, naltrexone-bupropion combined with structured lifestyle counselling produced greater weight loss and more substantial improvements in hepatic steatosis and fibrosis risk compared to lifestyle changes alone.
Ultimately, the key clinical message is that achieving and sustaining significant weight loss remains the most effective strategy for improving MASLD outcomes, and naltrexone-bupropion is a valuable tool in helping patients reach that goal.

Source/read full Paper: https://doi.org/10.1111/dom.70071

LEARN MORE ABOUT THE MUSLIM WEIGHT MANAGEMENT